The effect of CYP2D6 genotype on the dose-exposure relationship for atomoxetine has not been well characterized in children. Children 6-17 years of age diagnosed with ADHD were stratified byCYP2D6 genotype into groups with 0 (PM, n=4), 0.5 (IM, n=3), one (EM1, n=8) or two (EM2, n=8) functional alleles) and administered a single 0.5 mg/kg oral dose of atomoxetine. Plasma and urine samples were collected for 24 (IM, EM1 and EM2) or 72 hours (PMs). Dose-corrected atomoxetine systemic exposure (AUC00-∞ ) varied 29.6-fold across the study cohort, ranging from 4.4±2.7 µM*h in EM2s to 5.8±1.7 µM*h, 16.3±2.9 µM*h and 50.2±7.3 µM*h in EM1s, IMs and PMs, respectively (p<0.0001). Simulated steady state profiles at the maximum FDA-recommended dose suggest that most patients are unlikely to attain adequate ATX exposures. These data support the need for individualized dosing strategies for more effective use of the medication.
